6505--Metformin IR Tablets
ID: 36E79725R0041Type: Solicitation
AwardedJun 11, 2025
$36.3M$36,263,726
AwardeeGOLDEN STATE MEDICAL SUPPLY, INC. CAMARILLO 93012
Award #:36E79725D0028
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/cc47376feaab4b819d5ab4655988c447/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Metformin HCL IR Tablets as part of its pharmaceutical prime vendor programs, which also serve the Department of Defense (DoD). Offerors are required to submit pricing for various bottle sizes and quantities, ensure compliance with FDA regulations, and adhere to the Drug Supply Chain Security Act (DSCSA), including providing a unique National Drug Code (NDC) for each product. This procurement is crucial for maintaining a reliable source of pharmaceutical products, ensuring consistent availability and pricing while meeting federal regulatory standards. Interested parties should contact Senior Contract Specialist Teresa Hussain at teresa.hussain@va.gov for further details, and proposals must be submitted in accordance with the outlined requirements within the specified timeframe.

    Point(s) of Contact
    Teresa HussainSenior Contract Specialist
    teresa.hussain@va.gov
    Files
    Title
    Posted
    36E79725R0041_1.docx
    The VA National Acquisition Center is preparing to issue Request for Proposal (RFP) 36E79725R0041 for an unrestricted procurement of Metformin HCL IR Tablets to supply the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and other federal health entities. The contract will be awarded to a responsible offeror capable of ensuring an uninterrupted supply for one year, with four additional one-year options available. Offerors must provide the exact drug name and a unique National Drug Code (NDC), ensuring their label is the sole identifier on the product. The solicitation is set to be issued electronically in compliance with FAR Part 12 around April 14, 2025, with a closing date of April 29, 2025. Interested parties should refer to SAM.gov for updates and amendments, as paper copies will not be distributed. Teresa Hussain is the main point of contact for any inquiries regarding this procurement.
    36E79725R0041_METF_IR_04_14_2025.docx
    The document outlines the solicitation for a contract with the Department of Veterans Affairs (VA) regarding the supply of Metformin HCL IR Tablets as part of the pharmaceutical prime vendor programs for both the VA and the Department of Defense (DoD). It specifies the necessary proposal submissions, including pricing for various bottle sizes and quantities, adherence to FDA regulations, and strict compliance with the Drug Supply Chain Security Act (DSCSA). Offerors must provide a unique National Drug Code (NDC) for each product and must include a 0.5% Cost Recovery Fee in their prices. The contract will have an implementation period followed by a one-year ordering period with up to four additional one-year options. Offerors must prove the availability of supply sources, specifically if they are distributors, and ensure all products meet FDA Good Manufacturing Practices (cGMP). The document details requirements for backorders, recalls, product registration, and consent for manufacturing facilities. Overall, the solicitation aims to establish a reliable source for pharmaceutical products, ensuring consistent availability and pricing while adhering to federal regulations and participation requirements from various government entities.
    36E79725R0041.docx
    The document outlines a federal Request for Proposal (RFP) from the Department of Veterans Affairs (VA) seeking bids for the supply of Metformin HCL IR Tablets across various dosages in collaboration with the Department of Defense (DoD) Pharmaceutical Prime Vendor Programs. It emphasizes the need for offerors to price products competitively for a base year and four optional years, incorporating a 0.5% Cost Recovery Fee. Offerors must provide unique National Drug Code (NDC) numbers for all proposed drug products and maintain compliance with FDA's Good Manufacturing Practices (cGMP). The RFP establishes a framework for order fulfillment through Prime Vendors, with stringent requirements for product availability, reporting, and barcoding. The contract aims to streamline procurement processes for VA and DoD, ensuring consistent drug supply across healthcare facilities. It includes sections on compliance, product safety, registration, and recall procedures, highlighting the need for a commitment to quality and regulatory standards throughout the contract duration. Overall, the document serves as a formal solicitation of vendors capable of meeting the specifications for pharmaceutical supplies, reflecting the government's objective to procure necessary drugs efficiently and at competitive pricing to support veteran and military healthcare needs.
    Similar Opportunities
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking information from domestic pharmaceutical manufacturers through a Request for Information (RFI) designated 36C77026Q0061, aimed at supporting the Consolidated Mail Outpatient Pharmacy (CMOP) in fulfilling its Open Market (OM) purchasing needs. The RFI seeks to identify both small and large businesses capable of providing a range of pharmaceutical products and ancillary items, with a focus on those manufactured in the United States, to enhance the supply chain for approximately 450,000 prescriptions mailed daily to Veterans. Interested manufacturers are required to submit detailed company and product information, including FDA-approved NDC numbers and operational capabilities, by March 15, 2026, at 4:30 PM CT. For further inquiries, respondents can contact Michael McAlhaney at Michael.McAlhaney@va.gov or (913) 684-1976.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    Metformin HCL ER
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Metformin HCL ER. Metformin HCL ER is a drug used to treat type 2 diabetes. This procurement is being conducted by DLA TROOP SUPPORT. For more information, contact Christopher Newman at christopher.newman@dla.mil or 2157372905.